Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

Jazz Pharmaceuticals (Nasdaq: JAZZ) will report 2026 first quarter financial results on May 5, 2026 after U.S. market close.

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will report 2026 first quarter financial results on May 5, 2026 after U.S. market close. Management will host a webcast at 4:30 p.m. ET to discuss results and provide a business and financial update.

Interested parties may register in advance; a replay will be available via the Investors section of the company website.

Argus Apr 22 session

+1.69% close to close Open Argus

Details

News Market Reaction – JAZZ

On Apr 22, the first trading day after this news, JAZZ closed 1.69% above the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Market Context

This announcement sets the timetable for Jazz’s Q1 2026 financial results on May 5, 2026, following ...

Analysis

This announcement sets the timetable for Jazz’s Q1 2026 financial results on May 5, 2026, following record $4.3B 2025 revenue and $4.25–$4.50B 2026 guidance. A prior earnings-date notice in February 2026 led to only a 0.37% move, suggesting such communications typically have limited standalone impact. Investors may watch how Q1 results track against guidance, while also monitoring ongoing clinical milestones and recent insider Form 4 activity for additional context around sentiment.

Key Figures

Q1 2026 earnings date: May 5, 2026 Earnings call time: 4:30 p.m. ET Suggested early registration: 15 minutes prior

Q1 2026 earnings date

May 5, 2026

Scheduled reporting of 2026 first quarter financial results

Earnings call time

4:30 p.m. ET

Webcast to discuss Q1 2026 results and business update

Suggested early registration

15 minutes prior

Recommended lead time for connecting to the webcast

Previous Earnings date Reports

1 past event · Latest: Feb 10

Same Type 1 event

1. Feb 10

   Earnings date notice

   24h Move

   +0.4%

   Announced Q4 and full-year 2025 results date and post-close webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-5-2026-302749086.html

SOURCE Jazz Pharmaceuticals plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Jazz Pharmaceuticals (JAZZ) report Q1 2026 earnings?

Jazz will report Q1 2026 results on May 5, 2026 after the U.S. market close. According to the company, management will discuss results and provide a business and financial update during the webcast at 4:30 p.m. ET.

What time is the Jazz Pharmaceuticals (JAZZ) earnings webcast on May 5, 2026?

The company will host its earnings webcast at 4:30 p.m. ET on May 5, 2026 following market close. According to the company, listeners should register in advance and join at least 15 minutes early to ensure a timely connection.

How can investors register for the Jazz Pharmaceuticals (JAZZ) May 5, 2026 webcast?

Investors can register in advance via the Investors section of the company website or the provided registration link. According to the company, registering at least 15 minutes before the webcast is recommended for timely connection and access to the live presentation.

Will a replay of the Jazz Pharmaceuticals (JAZZ) May 5, 2026 webcast be available?

Yes. A replay will be available via the Investors section of the company website after the live webcast. According to the company, the replay can be accessed on the investor events and presentations page for on-demand review by stakeholders.

What will Jazz Pharmaceuticals (JAZZ) management cover on the May 5, 2026 call?

Management will discuss the first quarter results and provide a business and financial update during the webcast. According to the company, the session is intended to review quarterly performance and offer relevant operational and financial context to investors.